Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | ATP4A | P20648 | 1/20 | 0.48 |
| ▸ | ATP4B | P51164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765017 | 0.95 | QPCT (0.56) | QPCTCYP19A1ATP4AATP4BSMN1; SMN2 | |
| SCHEMBL13201562 | 0.92 | ATP4A (0.53) | CYP19A1ATP4AATP4BKDM4ELMNA | |
| SCHEMBL13246360 | 0.91 | QPCT (0.50) | QPCTCYP19A1ATP4AATP4BSMN1; SMN2 | |
| SCHEMBL14189706 | 0.91 | ATP4A (0.52) | CYP19A1ATP4AATP4BMEN1HTT | |
| SCHEMBL16358259 | 0.85 | ATP4A (0.48) | CYP19A1ATP4AATP4BKDM4ELMNA | |
| SCHEMBL22397927 | 0.83 | MEN1 (0.55) | QPCTCYP19A1ATP4AATP4BSMN1; SMN2 | |
| SCHEMBL14996228 | 0.81 | ATP4A (0.53) | QPCTCYP19A1ATP4AATP4BSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9482307 | 0.80 | ATP4A (0.65) | ATP4AATP4BMAPTMEN1KMT2A | |
| SCHEMBL5564341 | 0.80 | ATP4A (0.52) | QPCTCYP19A1ATP4AATP4BMAPT | |
| SCHEMBL5046643 | 0.80 | ATP4A (0.52) | QPCTCYP19A1ATP4AATP4BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7601840-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2008127715-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158858-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | RNMT, VEGFA, VHL | QPCT 267/4885CYP19A1 1016/4885ATP4A 3565/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | QPCT 1290/4885CYP19A1 2020/4885ATP4A 4522/4885 |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | QPCT 106/4885CYP19A1 552/4885ATP4A 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.